Fascioliasis Treatment Market

Fascioliasis Treatment Market Overview

Fascioliasis is a parasitic infection caused by Fasciola hepatica and Fasciola gigantic which is transmitted via contaminated water and uncooked vegetables. It infects humans, cattle and sheep.

Fascioliasis has demonstrated symptoms of nausea, abdominal pain, vomiting, intermitted fever, eosinophilia and hepatomegaly. According to the World Health Organisation (WHO), fascioliasis has been reported in more than 75 nations worldwide with the prevalent infected global population of 2.4 million, with no single nation is risk-free of fascioliasis.

The severely affected areas include South America, East-Asia, and South-east Asia. Compromised hygiene and sanitation are the key reasons for the infections. The symptoms are visible at 9-11 weeks of infections. The diagnosis includes eosinophil count (>500–1000 per microlitre of blood), computer tomography scans and ultrasound. The approved medication for fascioliasis is Triclabendazole.

Coronavirus pandemic has jolted the market. Countries like China infected initially by Coronavirus which is the major global supplier of active pharmaceutical ingredients and chemicals. This has adversely impacted the fascioliasis treatment market. Although, the global fascioliasis treatment market is expected to pace with lucrative growth spurt with the restoration of normal situation, and with the ongoing progressive market augmentations.

Fascioliasis Treatment Market: Drivers and Restraints

The global fascioliasis treatment market is driven by the surging global fascioliasis infestations which are due to the close contact with livestock, prevalent in the , Latin America, Europe, South Asia, East Asia, Oceania and MEA.

Since these nations are heavily dependent on cattle and sheep for food and agriculture. The revamping healthcare facilities, increasing awareness, disposable incomes and the advancement of R&D for fascioliasis treatment drugs are fuelling the market.

Government has several dedicated supportive schemes along with WHO to increase the awareness of treatments, subsidized medicines and reimbursement policies. Government has active funding aids and programs to support the merging drug manufacturers for fascioliasis treatment.

However, the limited drugs, dosage issues, adverse reactions, resistances and longer medication period are the restraints for the global fascioliasis treatment market.

Although dedicated drug manufactures are deliberating to reduce the cost of medicines such as Triclabendazole. Also, development of more effective and safer medications such as Nitazoxanide, niclofolan emetine, chloroquine and heptachlor-para-xylol are underway after the recommendation by WHO.

Fascioliasis Treatment Market: Overview

The global fascioliasis treatment market is anticipated with a lucrative growth in future with the current progressive augmentation of the market, the surging infestations and drug demands. By treatment, Triclabendazole rules the market as being the major drug for fascioliasis, is effective for both acute and chronic fascioliasis, with high efficacy and mild adverse effects.

Nitazoxanide is understudy to develop as a safer medication and its market is growing at a faster rate. By Distribution Channels, Hospital Pharmacy is the largest market of fascioliasis treatment, driven by the doctor’s diagnosis and prescriptions, reimbursements and government ties.

Fascioliasis Treatment Market: Regional Outlook

The global fascioliasis treatment market is dominated by Latin America with the increasing cases of fascioliasis due to the heavy contact with livestock, compromised hygiene and increasing awareness. The regions driving the Latin America fascioliasis treatment market include Peru, Chile, Argentina and Bolivia, with increasing prevalence of fascioliasis, government aid and treatment availability.

Middle East & Africa fascioliasis treatment market are also emerging due to the surging cases in Africa, Egypt, Zimbabwe, Cameroon and Senegal, coupled with the government aid. Asia pacific region is also elevating due to South-Asian countries such as India, Bangladesh, Vietnam and East Asian countries with rising burden of fascioliasis, poor sanitations and treatment availability.

However, Europe and North America have negligible fascioliasis treatment market and laggard growth rate due to low cases, strict sanitation and hygiene, and food standards.

Fascioliasis Treatment Market: Key Players

The key players of global fascioliasis treatment market include

• Novartis
• Alivira Animal Health Limited
• Merck & Co.
• Janssen
• Hebei Veyong Pharmaceutical Co. Ltd
• Norbrook
• Pfizer
• Procyon Life Sciences
• Ipca Laboratories and Hangzhou Think Chemical Co. Ltd.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Indication
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Fascioliasis Treatment Market: Segmentation

The global fascioliasis treatment market can be segmented into Treatment and Distribution Channels.

Treatment

• Triclabendazole
• Nitazoxanide

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy